Tibolone in hormone replacement therapy (part 1)

Artur J. Jakimiuk; Jacek Tomaszewski; Michał Bogusiewicz

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

6/2003
vol. 2

Send email

Copy url:

abstract:

Tibolone in hormone replacement therapy (part 1)

Artur J. Jakimiuk

,

Jacek Tomaszewski

,

Michał Bogusiewicz

(Prz Menopauz 2003, 6: 32–41)

Online publish date: 2003/12/16

View full text Get citation

Since over 40 years hormone replacement therapy (HRT) is a standard treatment for menopausal symptoms. Quality of life improvement caused by the use of HRT was regarded to be beneficial for bone and cardiovascular system. However, recent studies showed that the prolonged use of HRT may be associated with increased risk of breast cancer. Moreover, HERS and WHI trials changed accepted opinion on use of hormone therapy in the primary and secondary prevention of cardiovascular diseases. Tibolone, a drug acting by a unique mechanism, since 1988 has been widely used in over 70 countries. This review presents contemporary data on the effect of tibolone on the breast, bone, lipids and cardiovascular system.

keywords:

Tibolone in hormone replacement therapy (part 1)

Artur J. Jakimiuk , Jacek Tomaszewski , Michał Bogusiewicz

menopause, hormone replacement therapy, tibolone

Artur J. Jakimiuk

,

Jacek Tomaszewski

,

Michał Bogusiewicz